Zelavespib

• Description :

  Zelavespib (PU-H71) is a potent Hsp90 inhibitor, with an IC50 of 51 nM in MDA-MB-468 cells.

• Product Name Alternative :

  PU-H71

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  HSP

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/zelavespib.html

• Purity :

  99.93

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  CC(C)NCCCN1C(SC2=C(C=C3OCOC3=C2)I)=NC4=C(N=CN=C14)N

• Molecular Formula :

  C18H21IN6O2S

• Molecular Weight :

  512.37

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Caldas-Lopes E, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A. 2009 May 19;106 (20) :8368-73.|[2]Guo A, et al. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. Oncogene. 2017 Jun 15;36 (24) :3441-3449.|[3]Qu Z, et al. PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α. Mol Cell Biochem. 2014 Jan;386 (1-2) :135-42.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  HSP90

• CAS Number :

  [873436-91-0]